An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity-Reference-Cited by-同舟云学术

An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity

Published:2018-08-23 Issue:10 Volume:70 Page:1557-1564
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis Rheumatol

Author:

Tran-Duy An¹,Ghiti Moghadam Marjan¹,Oude Voshaar Martijn A. H.¹,Vonkeman Harald E.¹,Boonen Annelies²,Clarke Philip³,McColl Geoff³,ten Klooster Peter M.¹,Zijlstra T. R.⁴,Lems Willem F.⁵,Riyazi N.⁶,Griep E. N.⁷,Hazes J. M. W.⁸,Landewé Robert⁹,Bernelot Moens Hein J.¹⁰^ORCID,van Riel Piet L. C. M.¹¹,van de Laar Mart A. F. J.¹,Jansen T. L.¹²,

Affiliation:

1. Arthritis Center Twente; Medisch Spectrum Twente; and University of Twente; Enschede The Netherlands

2. Maastricht University Medical Center and Maastricht University; Maastricht The Netherlands

3. University of Melbourne; Melbourne Victoria Australia

4. Isala Medical Center; Zwolle The Netherlands

5. VU University Medical Center and Reade Medical Center; Amsterdam The Netherlands

6. Haga Medical Center; The Hague The Netherlands

7. Antonius Medical Center; Sneek The Netherlands

8. Erasmus University Medical Center; Rotterdam The Netherlands

9. AMC Amsterdam; Amsterdam The Netherlands

10. Ziekenhuisgroep Twente; Almelo and Hengelo The Netherlands

11. Radboud University Medical Center; Nijmegen The Netherlands

12. Viecurie Medical Center; Venlo The Netherlands

Funder

ZonMw

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.40546/fullpdf

Reference37 articles.

1. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases;Gabriel;Arthritis Res Ther,2009

2. The burden of illness of rheumatoid arthritis;Boonen;Clin Rheumatol,2011

3. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force;Smolen;Ann Rheum Dis,2016

4. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis;Singh;Arthritis Rheumatol,2016

5. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy;Yazici;Bull NYU Hosp Jt Dis,2008

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies;Expert Review of Pharmacoeconomics & Outcomes Research;2023-08-28

2. Cost–utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the Netherlands;Annals of the Rheumatic Diseases;2023-07-09

3. Treatment patterns of individualized real-life tapering approaches based on shared decision-making in rheumatoid arthritis;Zeitschrift für Rheumatologie;2023-06-23

4. Tapering biologic DMARDs in rheumatoid arthritis;Current Opinion in Pharmacology;2022-12

5. Nitric Oxide Scavenging and Hydrogen Sulfide Production Synergistically Treat Rheumatoid Arthritis;Advanced Healthcare Materials;2022-11-15